Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 + LP002 in Advanced Melanoma
NCT04756934Phase 1Unknown
- Sponsor
- Taizhou Houde Aoke Technology
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of LP002 and pucotenlimab in melanoma (5 arms), sponsored by Taizhou Houde Aoke Technology. Primary endpoints: Dose Limiting Toxicity rate at 6 months, Adverse Events at 2 years and 2 more. Status: unknown.
02
Drugs
LP002pucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04756934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756934.